First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
Reports of ChAdOx1 vaccine–associated thrombocytopenia and vascular adverse events have led to some countries restricting its use. Using a national prospective cohort, we estimated associations between exposure to first-dose ChAdOx1 or BNT162b2 vaccination and hematological and vascular adverse even...
Main Authors: | Simpson, CR, Shi, T, Vasileiou, E, Katikireddi, SV, Kerr, S, Moore, E, McCowan, C, Agrawal, U, Shah, SA, Ritchie, LD, Murray, J, Pan, J, Bradley, DT, Stock, SJ, Wood, R, Chuter, A, Beggs, J, Stagg, HR, Joy, M, Tsang, RSM, de Lusignan, S, Hobbs, R, Lyons, RA, Torabi, F, Bedston, S, O'Leary, M, Akbari, A, McMenamin, J, Robertson, C, Sheikh, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2021
|
Similar Items
-
Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
by: Simpson, CR, et al.
Published: (2022) -
COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
by: Agrawal, U, et al.
Published: (2021) -
First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales
by: Kerr, S, et al.
Published: (2022) -
Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
by: Colin R. Simpson, et al.
Published: (2022-08-01) -
First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
by: Steven Kerr, et al.
Published: (2022-02-01)